Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)
Entwistle & Cappucci LLP has launched an investigation into potential federal securities law violations regarding Cerevel Therapeutics Holdings (NASDAQ: CERE). The investigation focuses on the period between October 11, 2023, and December 6, 2023, particularly concerning a secondary public offering where Cerevel issued approximately 19 million shares at $22.81 per share on October 16, 2023.
Less than two months after this offering, AbbVie Inc. announced its acquisition of Cerevel at $45.00 per share. The law firm is specifically investigating claims related to stock purchases by certain Company insiders during this period.
Entwistle & Cappucci LLP ha avviato un'indagine su potenziali violazioni delle leggi federali sui titoli riguardanti Cerevel Therapeutics Holdings (NASDAQ: CERE). L'indagine si concentra sul periodo compreso tra l'11 ottobre 2023 e il 6 dicembre 2023, in particolare riguardo a un'offerta pubblica secondaria in cui Cerevel ha emesso circa 19 milioni di azioni a $22.81 per azione il 16 ottobre 2023.
Meno di due mesi dopo questa offerta, AbbVie Inc. ha annunciato l'acquisizione di Cerevel a $45.00 per azione. Lo studio legale sta indagando specificamente su affermazioni relative agli acquisti di azioni da parte di alcuni dirigenti dell'azienda durante questo periodo.
Entwistle & Cappucci LLP ha lanzado una investigación sobre posibles violaciones de las leyes federales de valores en relación con Cerevel Therapeutics Holdings (NASDAQ: CERE). La investigación se centra en el período comprendido entre el 11 de octubre de 2023 y el 6 de diciembre de 2023, particularmente en relación con una oferta pública secundaria donde Cerevel emitió aproximadamente 19 millones de acciones a $22.81 por acción el 16 de octubre de 2023.
Menos de dos meses después de esta oferta, AbbVie Inc. anunció su adquisición de Cerevel a $45.00 por acción. El bufete de abogados está investigando específicamente las afirmaciones relacionadas con las compras de acciones por parte de ciertos insiders de la empresa durante este período.
Entwistle & Cappucci LLP는 Cerevel Therapeutics Holdings (NASDAQ: CERE)에 대한 연방 증권법 위반 가능성에 대한 조사를 시작했습니다. 이 조사는 2023년 10월 11일부터 2023년 12월 6일 사이의 기간에 중점을 두고 있으며, 특히 Cerevel이 2023년 10월 16일에 약 1900만 주를 $22.81 per 주에 발행한 2차 공모와 관련이 있습니다.
이 오퍼링 이후 두 달도 안 되어, AbbVie Inc.는 Cerevel을 $45.00 per 주에 인수한다고 발표했습니다. 이 법무법인은 이 기간 동안 특정 회사 내부자의 주식 구매와 관련된 주장에 대해 구체적으로 조사하고 있습니다.
Entwistle & Cappucci LLP a lancé une enquête sur de potentielles violations des lois fédérales sur les valeurs mobilières concernant Cerevel Therapeutics Holdings (NASDAQ: CERE). L'enquête se concentre sur la période allant du 11 octobre 2023 au 6 décembre 2023, en particulier concernant une offre publique secondaire où Cerevel a émis environ 19 millions d'actions à $22.81 par action le 16 octobre 2023.
Moins de deux mois après cette offre, AbbVie Inc. a annoncé son acquisition de Cerevel à $45.00 par action. Le cabinet d'avocats enquête spécifiquement sur des allégations liées aux achats d'actions par certains initiés de l'entreprise pendant cette période.
Entwistle & Cappucci LLP hat eine Untersuchung zu möglichen Verstößen gegen das Bundeswertpapierrecht im Zusammenhang mit Cerevel Therapeutics Holdings (NASDAQ: CERE) eingeleitet. Die Untersuchung konzentriert sich auf den Zeitraum vom 11. Oktober 2023 bis zum 6. Dezember 2023, insbesondere im Hinblick auf ein sekundäres öffentliches Angebot, bei dem Cerevel am 16. Oktober 2023 etwa 19 Millionen Aktien zu $22.81 pro Aktie ausgegeben hat.
Weniger als zwei Monate nach diesem Angebot gab AbbVie Inc. die Übernahme von Cerevel zu $45.00 pro Aktie bekannt. Die Kanzlei untersucht insbesondere Ansprüche im Zusammenhang mit Aktienkäufen durch bestimmte Insider des Unternehmens während dieses Zeitraums.
- AbbVie's acquisition price of $45.00 per share represents a 97.3% premium over the secondary offering price
- Investigation into potential federal securities law violations regarding insider stock purchases
- Timing of secondary offering at $22.81 raises concerns as it occurred just before AbbVie's acquisition at nearly double the price
Cerevel was a publicly traded biopharmaceutical company that was acquired by AbbVie, Inc. in August 2024. On October 16, 2023, Cerevel conducted a secondary public stock offering of approximately 19 million shares for
If you sold Cerevel (NASDAQ: CERE) securities from October 11, 2023 through December 6, 2023, or have other information concerning these issues, please contact attorneys Robert N. Cappucci or Andrew M. Sher at 212-894-7200, or via e-mail at rcappucci@entwistle-law.com or asher@entwistle-law.com.
About Entwistle & Cappucci
Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients globally in the most complex and challenging legal matters. Our practice encompasses all areas of litigation, including securities, antitrust, corporate transactions, general corporate and commercial, creditor’s rights and bankruptcy, corporate governance and fiduciary duty, government affairs, insurance, investigations and white-collar defense. Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250331404862/en/
Robert N. Cappucci, Esq. (rcappucci@entwistle-law.com)
Andrew M. Sher, Esq. (asher@entwistle-law.com)
Entwistle & Cappucci LLP
www.entwistle-law.com
230 Park Avenue, 3rd Floor
Telephone: (212) 894-7200
Source: Entwistle & Cappucci LLP
FAQ
What is the price difference between Cerevel's (CERE) secondary offering and AbbVie's acquisition price?
When did Cerevel Therapeutics (CERE) conduct its secondary public offering?
What is the timeframe of Entwistle & Cappucci's investigation into Cerevel (CERE)?
What specific aspects of Cerevel's (CERE) stock transactions are being investigated?
